TITLE

Medicare: Appropriate Dispensing Fee Needed for Suppliers of Inhalation Therapy Drugs: GAO-05-72

AUTHOR(S)
Dummit, Laura A.
PUB. DATE
October 2004
SOURCE
GAO Reports;10/12/2004, p1
SOURCE TYPE
Government Document
DOC. TYPE
Report
ABSTRACT
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) revised the payment formula for most of the outpatient drugs, including inhalation therapy drugs, covered under Medicare part B. Under the revised formula, effective 2005, Medicare's payment is intended to be closer to acquisition costs. The Centers for Medicare & Medicaid Services (CMS), the agency that administers Medicare, also pays suppliers of inhalation therapy drugs a $5 per patient per month dispensing fee. Suppliers have raised concerns that once drug payments are closer to acquisition costs, they will no longer be able to use overpayments on drugs to subsidize dispensing costs, which they state are higher than $5. As directed by MMA, GAO (1) examined suppliers' acquisition costs of inhalation therapy drugs and (2) identified costs to suppliers of dispensing inhalation therapy drugs to Medicare beneficiaries. Using cost data obtained from 12 inhalation therapy suppliers that accounted for more than 42 percent of 2003 Medicare inhalation therapy payments, GAO found that 2003 acquisition costs for the three inhalation therapy drugs representing approximately 98 percent of Medicare inhalation therapy drug expenditures varied widely. For example, per unit acquisition costs for ipratropium bromide, the inhalation therapy drug with the highest Medicare expenditures, ranged from $0.23 to $0.64. Although costs varied, they were not always lower for the 4 largest suppliers. The lowest acquisition cost for ipratropium bromide was obtained by one of the small suppliers, and the highest by one of the large suppliers. GAO estimated that the 2003 Medicare payment rate per patient, per month was between $119 to $129 higher than suppliers' acquisition costs for a typical monthly supply of albuterol sulfate and between $162 to $187 higher for a typical monthly supply of ipratropium bromide. GAO estimated 2003 per patient monthly dispensing costs of $7 to $204 for the 12 inhalation therapy suppliers, which included patient care costs, such as pharmacy and shipping, and administrative and overhead costs, such as billing. Large suppliers did not necessarily have lower dispensing costs. Because Medicare payments for drugs have been much higher than suppliers' acquisition costs, suppliers indicated they were able to provide services that benefited both beneficiaries and their physicians, a fact that raises questions about the services necessary to dispense inhalation therapy drugs. For example, several suppliers reported that they incur substantial costs to ship drugs overnight to beneficiaries; most did so on an as-needed basis, although one did so routinely. All suppliers in GAO's sample made phone calls to beneficiaries to ask them if they needed medication refills, to coordinate a refill delivery, and to check on the beneficiaries' compliance with their prescribed drug regimens. Most suppliers made these calls on a monthly basis, but one reported that it did so twice a month.
ACCESSION #
18174516

 

Related Articles

  • MEDICARE. Cosgrove, James C. // GAO Reports;02/03/2012, p1 

    The article presents a report by the U.S. Government Accountability Office (GAO) to the Chairman, of the U.S. Senate's Committee on Finance about Medicare and implantable medical devices (IMD). The letter expresses concern over the current payment system for IMDs. Currently, IMD manufacturers do...

  • Medicare: Improvements Needed to Address Improper Payments for Medical Equipment and Supplies: GAO-07-59. Aronovitz, Leslie G. // GAO Reports;3/6/2007, p1 

    The Centers for Medicare & Medicaid Services (CMS)--the agency that administers Medicare--estimated that the program made about $700 million in improper payments for durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) from April 1, 2005, through March 31, 2006. To protect...

  • Types of Providers Involved in Medicare Cases, and CMS Efforts to Reduce Fraud.  // GAO Reports;11/28/2012, preceding p1 

    The article discusses the report of the U.S. Government Accountability Office (GAO) on the type of providers that were investigated for Medicare fraud. It says that durable medical equipment suppliers and medical facilities are the frequent subjects of criminal fraud cases in 2010. It also...

  • MEDICARE: Covert Testing Exposes Weaknesses in the Durable Medical Equipment Supplier Screening Process. Kutz, Gregory D. // GAO Reports;8/4/2008, p1 

    The article presents a report from the U.S. Government Accountability Office (GAO) concerning the schemes to defraud the Medicare program. GAO enumerates the strategy to prevent fraud and abuse in the enrollment and inspection process of durable medical equipment, prosthetics, orthotics, and...

  • DME supplier reviews said lacking.  // Medical Device Daily;11/4/2008, Vol. 12 Issue 215, p3 

    The article reports on the findings of an investigation by the U.S. Government Accountability Office (GAO) into the flaws in Medicare's durable medical equipment (DME) program. According to the October 2008 GAO study, DME suppliers faild to maintain a physical facility or were not open and...

  • NOTABLE"ABLE.  // HomeCare Magazine;Jan2006, Vol. 29 Issue 1, p6 

    The article presents quotes on depicting the impact of the actions taken by the U.S. Congress on patients and the medical equipment industry. Administrator of the U.S. Centers for Medicare and Medicaid Services (CMS) Mark McClellan said that $9.5 billion reduction in improper Medicare payments...

  • GAO Says Private Plans Increasing Medicare Spending.  // PT: Magazine of Physical Therapy;Jun2008, Vol. 16 Issue 6, p83 

    The article presents the report released by the Government Accountability Office (GAO) on the spending for private health plans in the U.S. The report stated that Medicare spends more per beneficiary in Medicare Advantage (MA) compared to beneficiaries in the original Medicare fee-for-service...

  • Medicare Physician Fees: Geographic Adjustment Indices Are Valid in Design, but Data and Methods Need Refinement: GAO-05-119. Steinwald, A. Bruce // GAO Reports;3/11/2005, p1 

    The Medicare physician fee schedule adjusts physician fees for area differences in physicians' costs of operating a private medical practice. Three separate indices, known as geographic practice cost indices (GPCI), raise or lower Medicare fees in an area, depending on whether the area's...

  • MEDICARE PHYSICIAN PAYMENTS: Medicare and Private Payment Differences for Anesthesia Services. King, Kathleen M. // GAO Reports;8/27/2007, preceding pi 

    The article examines the differences between Medicare and private payments for anesthesia services in the U.S. Usually, anesthesia practitioners, such as anesthesiologists and certified registered nurse anesthetists, administer these medical services. According to a government-sponsored survey,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics